Azitra (AZTR) Income from Continuing Operations (2022 - 2026)
Azitra (AZTR) reported Income from Continuing Operations of 3927240.0 for Q1 2026, down 27.99% on a YoY basis from 5453903.56 in Q1 2025, and down 75.83% quarter-over-quarter from 2233504.0 in Q4 2025.
Azitra (AZTR) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Azitra has reported Income from Continuing Operations for 5 years, with the latest figure at 3927240.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 27.99% year-over-year to 3927240.0; the trailing twelve-month figure through Mar 2026 stood at 11814265.0 (down 29.78% YoY), and the FY2025 full-year result was 10955370.0, down 22.17% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 3927240.0, down from 2233504.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1009491.0 in Q3 2024, with the low at 4429528.0 in Q2 2023.
- Historically, Income from Continuing Operations has averaged 2644066.12 across 5 years, with a median of 2544586.5 in 2023.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 48.05% — and 2025, when it tumbled 173.85%.
- Azitra's Income from Continuing Operations stood at 2882439.0 in 2022, then climbed by 14.87% to 2453785.0 in 2023, then climbed by 2.47% to 2393133.0 in 2024, then grew by 6.67% to 2233504.0 in 2025, then sank by 75.83% to 3927240.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3927240.0 (Q1 2026), 2233504.0 (Q4 2025), and 2764528.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | -3.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.93 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Sep 30, 2025 | -2.76 Mn |
| Jun 30, 2025 | -2.89 Mn |
| Mar 31, 2025 | -3.07 Mn |
| Dec 31, 2024 | -2.39 Mn |
| Sep 30, 2024 | -1.01 Mn |
| Jun 30, 2024 | -2.63 Mn |
| Mar 31, 2024 | -2.93 Mn |
| Dec 31, 2023 | -2.45 Mn |
| Sep 30, 2023 | -1.94 Mn |
| Jun 30, 2023 | -4.43 Mn |
| Mar 31, 2023 | -2.46 Mn |
| Dec 31, 2022 | -2.88 Mn |
| Sep 30, 2022 | -2.40 Mn |
| Jun 30, 2022 | -1.89 Mn |